Lupus News and Research

Latest Lupus News and Research

Early uMSC transplantation may treat lupus nephritis

Human umbilical cord blood-derived mensenchymal stem cells have been found to offer benefits for treating lupus nephritis when transplanted into mouse models of systemic lupus erythematosus.

12 Apr 2011

ALR announces medical research grant awards to cure lupus

The Alliance for Lupus Research – the world's largest private funder of lupus research – today announced its most recent medical research grant awards, totaling $3.6 million, which support the ALR mission of finding better treatments and ultimately preventing and curing systemic lupus erythematosus, a debilitating autoimmune disease.

7 Apr 2011

NYC scientists receive $420,000 S.L.E. Lupus Foundation grant for new research

New York City's S.L.E. Lupus Foundation is pleased to name the latest recipients of its Career Development and Basic Science Fellowships: Josephine Isgro, MD of Hospital for Special Surgery, Dipyaman Ganguly, PhD of Columbia University Medical Center, and Yi Yan, PhD of the Feinstein Institute at North Shore-Long Island Jewish Hospital.

6 Apr 2011

Idera presents IMO-3100 Phase 1 trial data in autoimmune diseases at Keystone Symposia

Idera Pharmaceuticals, Inc. today announced the presentation of data from its multiple-dose Phase 1 clinical trial of IMO-3100 in healthy subjects.

5 Apr 2011

Scientists engineer new protein that prevents HIV virus entry into cells

In what could be a potential breakthrough in the battle against AIDS and a major development in the rational design of new drugs, scientists have engineered a new protein that prevents the virus from entering cells.

1 Apr 2011

Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

Merck, known as MSD outside of the United States and Canada, announced results from several new data analyses from the pivotal Phase III studies evaluating the addition of its investigational oral protease inhibitor VICTRELIS to peginterferon alfa-2b and ribavirin in adult patients with chronic hepatitis C virus genotype 1 infection.

1 Apr 2011

Lupus nephritis ESRD study finds increase in incidence rates among children, African Americans

New research documenting changes in the incidence and outcomes of end-stage renal disease in the U.S. between 1995 and 2006, found a significant increase in incidence rates among patients 5 to 39 years of age and in African Americans.

28 Mar 2011

AARDA report on American economic impact of AD released at congressional briefing

A new report by the American Autoimmune Related Diseases Association examining the economic impact of autoimmune disease on Americans, their families and the United States was released today at a congressional briefing as part of AARDA's 2011 National Autoimmune Diseases Awareness Month activities.

23 Mar 2011

Genetic errors in women linked to increased risk of preeclampsia

Scientists have identified genetic errors in women with autoimmune diseases that increase the risk of preeclampsia, a potentially life-threatening condition that occurs in 10 percent of all pregnancies.

23 Mar 2011

NasVax reports positive results from Phase 2a trial of oral immunotherapy for non-alcoholic steatohepatitis

NasVax announces the success of a Phase 2a clinical trial of a new oral immunotherapy for non-alcoholic steatohepatitis (NASH), an inflammatory disease associated with fatty liver disease and the metabolic syndrome.

21 Mar 2011

APS ACTION brings experts together to improve patient outcomes

Motivated by the lack of treatment options for patients with antiphospholipid syndrome, rheumatology researchers convened an international committee to address the problem directly.

17 Mar 2011

New study: Positive outcomes from gene therapy trial in patients with Parkinson's

A multi-center gene therapy trial for patients with advanced Parkinson's disease demonstrated reduced symptoms of the progressive movement disorder, according to a new study published in Lancet Neurology.

17 Mar 2011

Malaria drug shrinks, slows resistant pancreatic tumors

Dana-Farber Cancer Institute scientists report they have shrunk or slowed the growth of notoriously resistant pancreatic tumors in mice, using a drug routinely prescribed for malaria and rheumatoid arthritis.

16 Mar 2011

New drug for Lupus approved

A new drug for lupus has won U.S. approval. The drug, Benlysta from Human Genome Sciences Inc., is administered once a month intravenously.

12 Mar 2011

Scientific advances at Scripps Research lay foundation for new lupus drug Benlysta

Scientific advances at The Scripps Research Institute were key to laying the foundation for the new drug Benlysta® (belimumab), approved today by the U.S. Food and Drug Administration. Benlysta®, which treats the most common type of lupus, is the first in a new class of pharmaceuticals that prevents the body from attacking its own critical tissues.

11 Mar 2011

Idera reports $6.0 million net loss for fourth quarter 2010

Idera Pharmaceuticals, Inc. today reported financial results for the fourth quarter and year ended December 31, 2010.

10 Mar 2011

ALR commits funding for new study to identify lupus susceptibility genes in multiple ethnicities

The Alliance for Lupus Research (ALR) – the world's largest private funder of lupus research – today announced funding of an important new study to identify lupus susceptibility genes in multiple ethnicities including African Americans, who are three times more likely than Caucasians to have the disease.

10 Mar 2011

FDA approves BENLYSTA for active, autoantibody-positive systemic lupus erythematosus

Human Genome Sciences, Inc. and GlaxoSmithKline PLC today announced that the U.S. Food and Drug Administration has approved BENLYSTA® (belimumab) for the treatment of adult patients with active, autoantibody-positive systemic lupus erythematosus (SLE) who are receiving standard therapy.

10 Mar 2011

Human Genome Sciences receives FDA approval for Benlysta to treat lupus

The U.S. Food and Drug Administration today approved Benlysta to treat patients with active, autoantibody-positive lupus who are receiving standard therapy, including corticosteroids, antimalarials, immunosuppressives, and nonsteroidal anti-inflammatory drugs.

9 Mar 2011

Merck to present VICTRELIS phase III study data against HCV at EASL annual meeting

Merck, known as MSD outside of the United States and Canada, announced that several new data analyses from Phase III studies of VICTRELIS, its investigational oral hepatitis C protease inhibitor, will be presented at The International Liver CongressTM / 46th European Association for the Study of the Liver annual meeting.

9 Mar 2011

Lupus News and Research

Latest Lupus News and Research

Early uMSC transplantation may treat lupus nephritis

ALR announces medical research grant awards to cure lupus

NYC scientists receive $420,000 S.L.E. Lupus Foundation grant for new research

Idera presents IMO-3100 Phase 1 trial data in autoimmune diseases at Keystone Symposia

Scientists engineer new protein that prevents HIV virus entry into cells

Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

Lupus nephritis ESRD study finds increase in incidence rates among children, African Americans

AARDA report on American economic impact of AD released at congressional briefing

Genetic errors in women linked to increased risk of preeclampsia

NasVax reports positive results from Phase 2a trial of oral immunotherapy for non-alcoholic steatohepatitis

APS ACTION brings experts together to improve patient outcomes

New study: Positive outcomes from gene therapy trial in patients with Parkinson's

Malaria drug shrinks, slows resistant pancreatic tumors

New drug for Lupus approved

Scientific advances at Scripps Research lay foundation for new lupus drug Benlysta

Idera reports $6.0 million net loss for fourth quarter 2010

ALR commits funding for new study to identify lupus susceptibility genes in multiple ethnicities

FDA approves BENLYSTA for active, autoantibody-positive systemic lupus erythematosus

Human Genome Sciences receives FDA approval for Benlysta to treat lupus

Merck to present VICTRELIS phase III study data against HCV at EASL annual meeting

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Lupus News and Research

Latest Lupus News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in